Study on the correlation between INR and the activity of coagulation factor II and X in patients with pulmonary thromboembolism with moderate and low intensity anticoagulation by oral warfarin_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

WU Chunting ¹ , ZHAO Jiahui ² , XIAO Yao ¹ , ZHANG Ying ¹ , ZHANG Wenmei ¹ , HUANG Yan ¹ ,  ZHU Guangfa ¹

1. Department of Respiratory and Critical Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, P. R. China;
2. Department of Urology Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, P. R. China;

Corresponding author：

ZHU Guangfa, Email: gfzhu6638@sina.com

Keywords：

Pulmonary thromboembolism; Coagulation factor Ⅱ; Coagulation factor Ⅹ; Warfarin

DOI：

10.7507/1671-6205.201908006

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To study the correlation between international normalized ratio (INR) and coagulation factor Ⅱ and Ⅹ in patients with pulmonary thromboembolism treated with warfarin at moderate and low intensity anticoagulation.Methods Fifty-one patients with pulmonary thromboembolism treated with warfarin orally were divided into low-intensity anticoagulation group (INR from 1.6 to 2.0) and standard-intensity anticoagulation group (INR form 2.0 to 3.0) according to their monitoring INR indices. The levels of coagulation factor Ⅱ and Ⅹ were measured, and the correlation between INR level and coagulation factor activity was compared.Results The INR of the low intensity anticoagulation group was 1.69±0.2 and the standard intensity anticoagulation group was 2.55±0.46. The corresponding activity of coagulation factor Ⅱ was (48.3±28.0)% and (24.0±8.0)% respectively. The activity of coagulation factor Ⅹ was (32.8±24.0)% and (16.7±6.0)%. There was a negative correlation between the activity of INR and coagulation factor Ⅱ and Ⅹ, with correlation coefficients of –0.903 and –0.459, respectively. Coagulation factor Ⅱ activity < 40%, coagulation factor Ⅹ activity inhibitory level < 25% is defined as anticoagulation effect. When coagulation factor Ⅱ activity level reaches anticoagulation effect, the corresponding minimum INR value was 1.56 and as to coagulation factor Ⅹ, the corresponding minimum INR value was 1.66.Conclusions INR is negatively correlated with the activity of coagulation factor Ⅱ and coagulation factor Ⅹ. With the increase of INR, the activity of coagulation factor Ⅱ and coagulation factor Ⅹ decrease. Low intensity anticoagulation could not effectively inhibit the activity of coagulation factor.

Citation： WU Chunting, ZHAO Jiahui, XIAO Yao, ZHANG Ying, ZHANG Wenmei, HUANG Yan, ZHU Guangfa. Study on the correlation between INR and the activity of coagulation factor II and X in patients with pulmonary thromboembolism with moderate and low intensity anticoagulation by oral warfarin. Chinese Journal of Respiratory and Critical Care Medicine, 2020, 19(4): 390-392. doi: 10.7507/1671-6205.201908006 Copy

1.	肺血栓栓塞症诊治与预防指南. 中华医学杂志, 2018, 98(14): 1060-1087.
2.	Doherty S. Pulmonary embolism: an update. Aust Fam Physician, 2017, 46(11): 816-820.
3.	Becattini C, Agnelli G. Risk stratification and management of acute pulmonary embolism. Hematology Am Soc Hematol Educ Program, 2016, 2016(1): 404-412.
4.	Becattini C, Franco L, Agnelli G. Acute pulmonary embolism after discharge: duration of therapy and follow-up testing. Semin Respir Crit Care Med, 2017, 38(1): 94-106.
5.	Couturaud F, Sanchez O, Pernod G, et al. Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: The PADIS-PE Randomized Clinical Trial. JAMA, 2015, 314(1): 31-40.
6.	Essien EO, Rali P, Mathai SC. Pulmonary embolism. Med Clin North Am, 2019, 103(3): 549-564.
7.	Gulati G, Hevelow M, George M, et al. International normalized ratio versus plasma levels of coagulation factors in patients on vitamin K antagonist therapy. Arch Pathol Lab Med, 2011, 135(4): 490-494.
8.	Costa IM, Serralheiro AI, Rodrigues M, et al. Usefulness of factor Ⅱ and factor Ⅹ as therapeutic markers in patients under chronic warfarin therapy. Biomed Pharmacother, 2010, 64(2): 130-132.

1. 肺血栓栓塞症诊治与预防指南. 中华医学杂志, 2018, 98(14): 1060-1087.
2. Doherty S. Pulmonary embolism: an update. Aust Fam Physician, 2017, 46(11): 816-820.
3. Becattini C, Agnelli G. Risk stratification and management of acute pulmonary embolism. Hematology Am Soc Hematol Educ Program, 2016, 2016(1): 404-412.
4. Becattini C, Franco L, Agnelli G. Acute pulmonary embolism after discharge: duration of therapy and follow-up testing. Semin Respir Crit Care Med, 2017, 38(1): 94-106.
5. Couturaud F, Sanchez O, Pernod G, et al. Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: The PADIS-PE Randomized Clinical Trial. JAMA, 2015, 314(1): 31-40.
6. Essien EO, Rali P, Mathai SC. Pulmonary embolism. Med Clin North Am, 2019, 103(3): 549-564.
7. Gulati G, Hevelow M, George M, et al. International normalized ratio versus plasma levels of coagulation factors in patients on vitamin K antagonist therapy. Arch Pathol Lab Med, 2011, 135(4): 490-494.
8. Costa IM, Serralheiro AI, Rodrigues M, et al. Usefulness of factor Ⅱ and factor Ⅹ as therapeutic markers in patients under chronic warfarin therapy. Biomed Pharmacother, 2010, 64(2): 130-132.

Chinese Journal of Respiratory and Critical Care Medicine

Study on the correlation between INR and the activity of coagulation factor II and X in patients with pulmonary thromboembolism with moderate and low intensity anticoagulation by oral warfarin

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content